Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Gynecologic 1

Conditions

Ovarian Neoplasms 27Fallopian Tube Neoplasms 24Uterine Cervical Neoplasms 6Brenner Tumor 6Pancreatic Neoplasms 3Endometrial Neoplasms 3Breast Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Endometrial Adenocarcinoma 2Cervical Adenocarcinoma 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Sertoli-Leydig Cell Tumor 1Sarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrence 1Rectal Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Penile Neoplasms 1Ovarian gynandroblastoma 1Neoplasms 1

Interventions

Paclitaxel 7Cisplatin 6pembrolizumab 5Carboplatin 5Bevacizumab 5liposomal doxorubicin 3Gemcitabine 3trebananib 2niraparib 2interferon gamma-1b 2dostarlimab 2catumaxomab 2atezolizumab 2anlotinib 2Topotecan 2Radiotherapy, Intensity-Modulated 2Ocoxin 2Itraconazole 2Injections 2Hyperthermic Intraperitoneal Chemotherapy 2Drug Therapy 2Docetaxel 2vosaroxin 1vistusertib 1pertuzumab 1peginterferon alfa-2b 1olaparib 1nintedanib 1lanreotide 1epothilone B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Disulfides × Gynecologic × Clear all
NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
1,052 enrolled 27 charts
Gynecologic

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡